Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 338

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 338
---
. The members of our team have been collectively involved
in the development and approval of multiple medtech and biopharmaceutical drug products.

Target Acquisitions

On August 7,
2022, Longevity entered into Contribution and Exchange Agreements (“C&E Agreements”) with Aegeria, Cerevast, and Novokera
and their respective stockholders or members. On January 25, 2023, the C&E Agreements were amended to, among other things, finalize
certain key provisions of the Target Acquisitions. The consummation of each Target Acquisition is conditioned upon the satisfaction or
waiver of certain closing conditions including amongst other items, (i) the closing of each of the other Target Acquisitions and (ii)
the closing of a business combination with a valuation of not less than $128 million and minimum aggregate unrestricted cash proceeds
available to fund the balance sheet at closing of $30 million. The foregoing conditions may be waived on behalf of each of Aegeria, Cerevast,
and Novokera by the representative of their respective stockholders or members as detailed in the C&E Agreements.

On June 26, 2023
the C&E Agreements were further amended to revise the definition of an Approved deSPAC Transaction to have a lock-up of 180 days for
directors, officers and 5% or greater stockholders of the post-transaction company.

On August 29,
2023, Longevity along with Aegeria, Cerevast and Novokera entered into the Third Amendment to the C&E Agreement to remove the closing
condition of minimum cash at closing of $30 million.

On August 8,
2024, Longevity terminated the C&E Agreement with Novokera pursuant to Section 10.1(b) of the C&E Agreement due to multiple conditions
not being satisfied or waived to close a business combination by October 25, 2023.

On August 8,
2024, the Company entered into amendments to the C&E Agreements with Aegeria and Cerevast (“Targets”) and each of the
Targets’ respective stockholders and unitholders pursuant to which certain provisions of the C&E Agreements were amended to,
among other things: modify the aggregate valuation assigned to Longevity reflecting a business combination and modify the allocation of
the transaction consideration among the Targets and FutureTech Capital.

| 176 |

Aegeria Soft Tissue LLC

Aegeria is a
clinical-stage